Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice von Kolář, Martin, Ďuricová, Dana, Bortlík, Martin, Pudilová, Karolína, Hrubá, Veronika, Machková, Naděžda, Mitrová, Katarína, Malíčková, Karin, Lukáš, Martin, Vašátko, Martin, Vaníčková, Radka, Lukáš, Milan

Volltext

Early vedolizumab trough levels are not associated with short-term response in patients with inflammatory bowel disease von Pudilová, Karolína, Kolář, Martin, Ďuricová, Dana, Malíčková, Karin, Hrubá, Veronika, Machková, Naděžda, Vaníčková, Radka, Mitrová, Karatína, Lukáš, Martin, Vašátko, Martin, Lukáš, Milan, Bortlík, Martin

Volltext

Mo1919 – Ustekinumab Efficiency As a Higher-Line Therapy in Association with Serum Levels in Patients with Crohn’s Disease von Kolar, Martin, Pudilova, Karolina, Bortlik, Martin, Duricova, Dana, Malickova, Karin, Hruba, Veronika, Machkova, Nadezda, Vanickova, Radka, Mitrova, Katarina, Lukas, Martin, Vasatko, Martin, Lukas, Milan

Volltext

Mo1894 – Early Vedolizumab Trough Levels are Not Associated with a Short-Term Response in Patients with Inflammatory Bowel Disease von Pudilova, Karolina, Duricova, Dana, Kolar, Martin, Malickova, Karin, Hruba, Veronika, Machkova, Nadezda, Vanickova, Radka, Mitrova, Katarina, Lukas, Martin, Vasatko, Martin, Lukas, Milan, Bortlik, Martin

Volltext

Ultrasonographic evaluation of the distal femoral and talar cartilage thicknesses in patients with poliomyelitis: a cross-sectional observational study von ANGEROVÁ, Yvona, MEZIAN, Kamal, KARA, Murat, PUDILOVÁ, Veronika, SOBOTOVÁ, Karolína, MICHALČINOVÁ, Klaudia, KONOPÁČOVÁ, Eva, ÖZÇAKAR, Levent

Volltext